CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Clinigen Limited is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Clinigen Limited
Pitcairn House Crown Square
Centrum 100
Phone: +44 1283495010p:+44 1283495010 BURTON UPON TRENT, Staffordshire,  DE14 2WW  United Kingdom
This company was Merged or Acquired on 3/31/2022.
The Company was acquired by a newly-formed company indirectly owned by the Triton Funds, Triley Bidco Limited.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Clinigen Limited, formerly known as Clinigen Group plc is a United Kingdom-based pharmaceutical services and products company. The Company's principal activities are focused on providing healthcare professionals (HCPs) and their patients with access to medicines. It operates through two segments: Services and Products. Its product brands include ACETYLCYSTEINE, COLECALCIFEROL, CARDIOXANE, ERWINASE / ERWINAZE, ETHYOL, FOLIC ACID COLONIS, FOSCAVIR, GABAPENTIN COLONIS, GLYCOPYRRONIUM BROMIDE, ILOPROST, IMUKIN / IMMUKIN / IMMUKINE, METFORMIN COLONIS, NORTRIPTYLINE COLONIS, PROLEUKIN and SAVENE, among others. The services provided by the Company includes clinical supplies management, managed access programs, real world data and medical science liaison (MSL). It operates in locations across North America, Europe, Africa, Japan and Asia Pacific. Its subsidiaries include Clinigen Healthcare B.V., Clinigen Clinical Trials Limited, Link Healthcare Singapore Pte. Limited and Clinigen South Africa (Pty) Limited, among others.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20216/30/2021Yes---Yes

Industries
SIC Code Description
5122 Drugs, drug proprietaries, and druggists' sundries
8741 Management services
8731 Commercial physical and biological research
7389 Business services, not elsewhere classified
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Non-Executive Chairman of the Board Elmar J.Schnee 62 9/1/2021 8/3/2021
Chief Executive Officer, Director Shaun E.Chilton 51 11/11/2016 1/1/2012
Interim Chief Financial Officer, Group Financial Controller RichardPaling 8/25/2021 8/25/2021
6 additional Officers and Directors records available in full report.

Business Names
Business Name
B&C Group Holding SA
B&C Invest SA
Cardioxane
69 additional Business Names available in full report.

General Information
Number of Employees: 1,013 (As of 6/30/2021)
Outstanding Shares: 133,367,000 (As of 12/31/2021)
Stock Exchange: LON
Federal Tax Id: 000008607


Copyright © 2022 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, August 19, 2022